<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356537</url>
  </required_header>
  <id_info>
    <org_study_id>Shire/CS03</org_study_id>
    <nct_id>NCT01356537</nct_id>
  </id_info>
  <brief_title>Home Therapy With VPRIV in Gaucher's Disease</brief_title>
  <official_title>Non Interventional Study of VPRIV® (Velaglucerase Alfa) Home Therapy in Patients With Gaucher's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to proof increasing patient satisfaction and preservation of
      quality of life in patients with Gaucher's Disease receiving their enzyme replacement therapy
      with VPRIV (Velaglucerase alfa)at their home setting compared to receiving the infusions at
      the clinic or at doctor's practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction estimated on a 10-ary Likert scale, quality of life estimated by SF-36 questionnaire</measure>
    <time_frame>comparison of baseline to 12 months value</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (per infusion) and severity of infusion-related side effects</measure>
    <time_frame>baseline compared to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Gaucher's Disease under VPRIV</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with proven Gaucher's Disease foreseen for home treatment with VPRIV
        (Velaglucerase alfa) at German Gaucher centers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with a confirmed diagnosis of Gaucher disease type 1

          -  Age&gt; 2 years

          -  patients who have at least 3 infusions (6 weeks) at least 5-year or 5-6 infusions
             (10-12 weeks) at 2 - to 4-year patients have received VPRIV ® and tolerate well

          -  The patient is compliant, the previous VPRIV ® infusions were / performed
             approximately every 2 weeks in the center during office visits

          -  The patient was already before inclusion in this study for a home infusion therapy and
             has consented to (or their legal representative)

          -  The patient / be lawful. Representative has consented in writing to participate in
             this study.

        Exclusion criteria:

        • The patient is participating in a clinical trial with a medicinal product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Landeskrankenhaus Bregenz</name>
      <address>
        <city>Bregenz</city>
        <zip>A-6900</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Huemer, MD</last_name>
      <phone>+43 (0)5574 401-6507</phone>
      <email>Martina.Huemer@lkhb.at</email>
    </contact>
    <investigator>
      <last_name>Martina Huemer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yildiz Yildiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privatuniversität Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian B. Lagler, MD</last_name>
      <phone>43 662 442002 1224</phone>
      <email>florian.lagler@pmu.ac.at</email>
    </contact>
    <investigator>
      <last_name>Florian B. Lagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKH, Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothea Möslinger, MD</last_name>
      <phone>+43-1-40400-3232</phone>
      <email>Dorothea.Moeslinger@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Vassiliki Konstantopoulou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Stulnig, MD</last_name>
      <phone>+43 (0)1 40400 4368</phone>
      <email>thomas.stulnig@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Stulnig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Thomas Stulnig, MD</last_name>
      <phone>+43 1 40400 4368</phone>
      <email>thomas.stulnig@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Stulnig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinology in the center</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Facharzt für Chirurgie und Orthopädie</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22607</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterological FOCUS PRACTICE Dr. med. Hans Werner Karch</name>
      <address>
        <city>Kirn</city>
        <zip>55606</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Köln</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Gruner-Ewald</last_name>
      <phone>+49 221 989 44717</phone>
      <email>bod.t.gruner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Achim Rothe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugen Mengel, Dr.</last_name>
      <phone>+49 6131 172781</phone>
      <email>mengel@kinder.klinik.uni-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Eugen Mengel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Group Practice, Drs Klaus Michels and Michels Alexander</name>
      <address>
        <city>Mühlhausen</city>
        <zip>D-92360</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Regenbogen, MD</last_name>
      <phone>+49-089-4140-5644</phone>
      <email>Claudia.Regenbogen@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Regenbogen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albrecht-Kossel-Institut für Neuroregeneration (AKos)</name>
      <address>
        <city>Rostock</city>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Rolfs, MD</last_name>
      <phone>+49 381 494 95 40</phone>
      <email>arndt.rolfs@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Arndt Rolfs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>D-19055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CA Prof. Peter Clemens, MD</last_name>
      <phone>+49-385 5202660</phone>
      <email>Peter.clemens@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Peter Clemens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Leichsenring, MD</last_name>
      <phone>0731 - 500 57143</phone>
      <email>michael.leichsenring@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Michael Leichsenring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin</name>
      <address>
        <city>Wallgau</city>
        <zip>D-82499</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

